India · Delayed Price · Currency is INR Tata Chemicals Earnings Call Transcripts
Fiscal Year 2026
-
Revenue declined 2% YoY due to subdued global demand and higher costs from geopolitical disruptions, but India showed robust growth and non-soda ash revenue rose 14%. Exceptional charges impacted profitability, while CapEx will focus on maintenance and strategic growth.
-
Soda ash markets remain oversupplied, pressuring prices and margins, with India showing growth and the US and UK focusing on operational efficiency and value-added products. CAPEX is concentrated in India and Asia, while cost control and selective market participation are prioritized.
-
Standalone performance was strong with revenue up 19% and profit after tax up 80% year-over-year, while consolidated results were impacted by one-time provisions and lower volumes. Global soda ash markets remain oversupplied, but Indian operations are stable and capacity expansions are planned.
-
Q1 FY26 delivered stable revenues and improved profitability, driven by higher volumes, cost efficiencies, and lower input costs, despite flat global demand and oversupplied markets. Outlook for FY26 remains positive with targeted EBITDA improvements and ongoing capacity expansions.
Fiscal Year 2025
-
Q4 saw revenue and margins under pressure from lower realizations, one-off UK costs, and weak US exports, but India and Kenya delivered volume growth. New capacities in India, UK, and Kenya are expected to offset UK soda ash exit, with CapEx peaking in FY 2025 and set to normalize.
-
Revenue declined 4% year-over-year due to pricing pressure, but India and U.S. volumes grew. CapEx will be phased to match cash flows, and the U.K. soda ash plant ceased operations with a one-time charge. Market prices are expected to remain low for the next 3–6 months.
-
Q2 FY25 saw 6% sequential revenue growth, driven by U.S. volumes, while Indian operations were impacted by heavy rains but have now stabilized. Major capacity expansions in India, U.S., and Kenya are on track, with a positive long-term demand outlook and margin recovery expected.
-
Stable demand and balanced supply supported operational performance, with India and the U.S. showing margin improvements due to lower costs and steady production. Capacity expansions in soda ash, sodium bicarbonate, and pharmaceutical salt are set to boost EBITDA by INR 400 crore annually.